ログイン
ランキング
お知らせ
ログイン
文献詳細
総説
文献概要
高齢化に伴い糖尿病も認知症も患者数は増加すると予想される。糖尿病は認知症発症を促進するため，糖尿病患者では軽度認知障害の段階で認知機能障害を早期発見することが重要である。MoCA（Montreal Cognitive Assessment）による筆者らの検討では，糖尿病教育入院中の72%の患者に糖尿病合併軽度認知障害が疑われた。糖尿病治療薬によるアルツハイマー病の治療が試みられ，糖尿病はパーキンソン病などの神経変性疾患との関連も指摘されている。
参考文献
1) 総務省統計局統計トピックスN.84統計からみた我が国の高齢者（65歳以上)——「敬老の日」にちなんで. http://www.stat.go.jp/data/topics/topi840.htm
2) 厚生労働省: 平成24年国民健康・栄養調査結果の概要. http://www.mhlw.go.jp/file/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/0000032813.pdf
3) 朝田 隆: 都市部における認知症有病率と認知症の生活機能障害への対応, 平成23年度-平成24年度総合研究報告書. 2013, pp1-46
4) Sommerfileld AJ, Deary IJ, Frier BM: Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care 27: 2335-2340, 2004
5) Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, et al: Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 29: 345-351, 2006
6) Huang CC, Chung CM, Leu HB, Lin LY, Chiu CC, et al: Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study. PLOS ONE 9: e87095, 2014
7) Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV: Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 15: 1565-1572, 2009
8) Rizzo MR, Marfella R, Barbieri M, Boccardi V, Vestini F, et al: Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care 33: 2169-2174, 2010
9) Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, et al; ACCORD trial group: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376: 419-430, 2010
10) Zoungas S, Patel A, Chalmers j, de Galan BE, Li Q, et al; ADVANCE collaborative Group: Sever hypoglycemia and risks of vascular events and death. N Engl J Med 363: 1410-1418, 2010
11) Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, et al: Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 10: 969-977, 2011
12) Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, et al: Glucose levels and risk of dementia. N Engl J Med 369: 540-548, 2013
13) Biessels GJ, Deary IJ, Ryan CM: Cognition and diabetes: a lifespan perspective. Lancet Neurol 7: 184-190, 2008
14) Crosby-Nwaobi RR, Sivaprasad S, Amiel S, Forbes A: The relationship between diabetic retinopathy and cognitive impairment. Diabetes Care 36: 3177-3186, 2013
15) Araki A, Ito H: Asymptomatic cerebral infarction on brain MR images and cognitive function in elderly diabetic patinets. Geriatr Gerontol Int 2: 206-214, 2002
16) Umegaki H, Iimuro S, Shinozaki T, Araki A, Sakurai T, et al: Risk factors associated with cognitive decline in the elderly with type 2 diabetes: baseline data analysis of the Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int 12: 103-109, 2012
17) 日本糖尿病学会（編・著): 糖尿病治療ガイド2014−2015．文光堂, 東京, 2014
18) McCrimmon RJ, Ryan CM, Frier BM: Diabetes and cognitive dysfunction. Lancet 379: 2291-2299, 2012
19) Van den Berg E, Reijmer YD, de Bresser J, Kessels RP, Kappelle LJ, et al: A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia 53: 58-65, 2010
20) Garcia-Casares N, Jorge RE, Garcia-Arnés JA, Acion L, Berthier ML, et al: Cognitive dysfunctions in middle-aged type 2 diabetic patients and neuroimaging correlations: a cross-sectional study. J Alzheimers Dis 42: 1337-1346, 2014
21) Winkler A, Dlugaj M, Weimar C, Jöckel KH, Erbel R, et al: Association of diabetes mellitus and mild cognitive impairment in middle-aged men and women. J Alzheimers Dis 42: 1269-1277, 2014
22) Nasreddine ZS, Phillips NA, Bédirian V. Charbonneau S, Whitehead V, et al: The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53: 695-699, 2005
23) Fujiwara Y, Suzuki H, Yasunaga M, Sugiyama M, Ijuin M, et al: Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int 10: 225-232, 2010
24) Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livington L, Graham C, et al: The MoCA well-suited screen for cognitive impairment in Parkinson disease. Neurology 75: 1717-1725, 2010
25) Murakami H, Fujita K, Futamura A, Sugimoto A, Kobayakawa M, et al: The Montreal Cognitive Assessment and Neurobehavioral cognitive status examination (COGNISTAT) are useful for screening mild cognitive impairment in Japanese patients with Parkinson's disease. Neurol Clin Neurosci 1: 103-108, 2013
26) Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, et al: The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Mov Disord 25: 401-404, 2010
27) Godefroy O, Fickl A, Roussel M, Auribault C, Bugnicourt JM, et al: Is the Montreal Cognitive Assessment superior to the Mini-Mental State Examination to detect poststroke cognitive impairment?: a study with neuropsychological evaluation. Stroke 42: 1712-1716, 2011
28) McLennan SN, Mathias JL, Brennan LC, Stewart S: Validity of the montreal cognitive assessment (MoCA) as a screening test for mild cognitive impairment (MCI) in a cardiovascular population. J Geriatr Psychiatry Neurol 24: 33-38, 2011
29) Alagiakrishnan K, Zhao N, Mereu L, Senior P, Senthilselvan A: Montreal Cognitive Assessment is superior to Standardized Mini-Mental Status Exam in detecting mild cognitive impairment in the middle-aged and elderly patients with type 2 diabetes mellitus. Biomed Res Int 2013: 186106, 2013
30) Sebaldt R, Dalziel W, Massoud F, Tangay A, Ward R, et al: Detection of cognitive impairment and dementia using the animal fluency test: the DECIDE study. Can J Neurol Sci 36: 599-604, 2009
31) Nandipati S, Luo X, Schimming C, Grossman H, Sano M: Cognition in non-demented diabetic older adults. Curr Aging Sci 5: 131-135, 2012
32) Mori Y, Futamura A, Murakami H, Kohashi K, Hirano T, et al: Increased detection of mild cognitive impairment with type 2 diabetes mellitus using the Japanese version of the Montreal Cognitive Assessment: a pilot study. Neurology and Clinical Neuroscience; article first published online, 11 Dec 2014
33) Fukuzawa R, Hanyu H, Sato T, Shimizu S, Koyama S, et al: Subgroups of Alzheimer's disease associated with diabetes mellitus based on brain imaging. Dement Geriatr Cogn Disord 35: 280-290, 2013
34) Li J, Shao YH, Gong YP, Lu YH, Liu Y, et al: Diabetes mellitus and dementia: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 18: 1778-1789, 2014
35) Cheng G, Huang C, Deng H, Wang H: Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 42: 484-491, 2012
36) Craft S, Watson GS: Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3: 169-178, 2004
37) Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, et al: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56: 1135-1140, 1999
38) Freiherr J, Hallschmid M, Frey WH 2nd, Brünner YF, Chapman CD, et al: Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27: 505-514, 2013
39) Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, et al: Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75: 764-770, 2010
40) Umegaki H: Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clin Interv Aging 9: 1011-1019, 2014
41) Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, et al: Physical activity, diet, and risk of Alzheimer disease. JAMA 302: 627-637, 2009
42) Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, et al: Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis 22: 569-579, 2010
43) Reiner M, Niermann C, Jekauc D, Woll A: Long-term health benefits of physical activity a systematic review of longitudinal studies. BMC Public Health 13: 813, 2013
44) Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, et al: Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156: 445-453, 2002
45) Verdelho A, Madureira S, Ferro JM, Baezner H, Blahak C, et al: Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. Stroke 43: 3331-3335, 2012
46) Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, et al: Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 68: 311-318, 2010
47) Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, et al: Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32: 1626-1633, 2011
48) Watson GS, Cholertion BA, Reger MA, Baker LD, Plymate SR, et al: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13: 950-958, 2005
49) Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, et al: Efficacy of rosiglitazone in a genetically defined population with mild to moderate Alzheimer's disease. Pharmacogenomics J 6: 246-254, 2006
50) Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, et al: Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 33: 1706-1711, 2010
51) Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, et al: Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geiatr Cogn Disord 30: 131-146, 2010
) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A 106: 3907-3912, 2009
53) Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG: Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arterioscler Thromb Vasc Biol 28: 1556-1562, 2008
54) Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, et al: A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77: 556-563, 2011
55) Craft S, Watson GS: Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3: 169-178, 2004
56) Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, et al: Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis 4: 337-344, 2014
57) Golimstok A, Cámpora N, Rojas JI, Fernandez MC, Elizondo C, et al: Cardiovascular risk factors and frontotemporal dementia: a case-control study. Transl Neurodegener 3: 13, 2014
掲載誌情報
